tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Repare Therapeutics Inc

RPTX
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
2.650USD
0.0000.00%
์ข…๊ฐ€ย 07/02, 13:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
114.24M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
TradingKey ๅ›พ่กจ
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

0.00%

5์ผ

0.00%

1๊ฐœ์›”

0.00%

6๊ฐœ์›”

+3.11%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

+1.92%

1๋…„

+84.03%

ํ•ต์‹ฌ ์ˆ˜์น˜
--์‹œ๊ฐ€
0.000์ตœ๊ณ ๊ฐ€
0.00๊ฑฐ๋ž˜๋Ÿ‰
์†์‹คP/E TTM
--๋™์  P/E ๋น„์œจ
--๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
2.84%ํšŒ์ „์œจ
2.650์ „์ผ ์ข…๊ฐ€
0.000์ตœ์ €๊ฐ€
0.00๋งค์ถœ์•ก
์†์‹ค์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
0.99P/B
0.00%๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
-43.35%ROA
2.66052์ฃผ ์ตœ๊ณ ๊ฐ€
0.89๊ฑฐ๋ž˜๋Ÿ‰ ๋น„์œจ
-84.69M์ˆœ์ด์ต
42.99M์ฃผ์‹
-1.6913์ฃผ๋‹น์ˆœ์ด์ต
0.99๋ฒ ํƒ€
-49.78%ROE
0.89052์ฃผ ์ตœ์ €๊ฐ€
1.14%๋ณ€๋™ ํญ
100.00%์ด ์ด์ต๋ฅ 
114.24M์‹œ๊ฐ€์ด์•ก
0.77๋ณด์ƒ/์œ„ํ—˜
3.02%์œ„ํ—˜๋ฅ 

TradingKey Repare Therapeutics Inc ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2026-01-27

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

Repare Therapeutics Inc์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•„์ฃผ ๊ฑด์ „ํ•œ ์ƒํƒœ์ด๋ฉฐ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ ์‚ฐ์—…์—์„œ 394๊ฐœ ์ค‘ 105์œ„ ๋žญํ‚น.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ง€๋‚œ ํ•œ ๋‹ฌ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๊ฐ€ ํ•ด๋‹น ๊ธฐ์—…์„ ๋งค์ˆ˜(์œผ)๋กœ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ตœ๊ณ  ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ 3.00์ž…๋‹ˆ๋‹ค.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ์ƒ์Šน ์ถ”์„ธ์ผ ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ํ‰๋ฒ”ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘์—ˆ์ง€๋งŒ, ๊ธฐ์—…์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ํƒ„ํƒ„ํ•ฉ๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

Repare Therapeutics Inc ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
105 / 394
์ „์ฒด ์ˆœ์œ„
221 / 4538
์‚ฐ์—…
์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ฏธ๋””์–ด ๋ณด๋„

์ตœ๊ทผ 24 ์‹œ๊ฐ„
๋ณด๋„ ์ˆ˜์ค€

๋งค์šฐ ๋‚ฎ์€
๋งค์šฐ ๋†’์€
์ค‘๋ฆฝ

Repare Therapeutics Inc ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
์„ฑ์žฅ ์ค‘
ํšŒ์‚ฌ๋Š” ์„ฑ์žฅ ๋‹จ๊ณ„์— ์žˆ์œผ๋ฉฐ, ์ตœ์‹  ์—ฐ๊ฐ„ ์ˆ˜์ต์€ ๋ฏธํ™” 53.48M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณ ์ˆ˜์ต ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์€ ์—…๊ณ„ ์„ ๋‘๋ฅผ ๋‹ฌ๋ฆฌ๊ณ  ์žˆ์œผ๋ฉฐ, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์ˆœ์ด์ต์€ ๋ฏธํ™” 53.48M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณต์ •ํ•œ ๊ฐ€์น˜
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ -1.57๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ์ค‘๊ฐ„ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค๋„
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 24.73M์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 27.95% ๊ฐ์†Œํ–ˆ์Šต๋‹ˆ๋‹ค.
์ œ์ž„์Šค ์‚ฌ์ด๋จผ์Šค๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž ์ œ์ž„์Šค ์‚ฌ์ด๋จผ์Šค์ด(๊ฐ€) ์ด ์ฃผ์‹ 724.16K์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.
์‹œ์žฅ ํ™œ๋™ ๊ฐ์†Œ
ํšŒ์‚ฌ๋Š” ํˆฌ์ž์ž๋“ค์˜ ๊ด€์‹ฌ์ด ์ค„์–ด๋“ค์–ด, ์ตœ๊ทผ 20์ผ๊ฐ„ ํšŒ์ „์œจ์ด -0.68์ž…๋‹ˆ๋‹ค.

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

0 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
--
ํ˜„์žฌ ๋“ฑ๊ธ‰
3.000
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+13.21%
์ƒ์Šน ์—ฌ๋ ฅ

Repare Therapeutics Inc ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

Repare Therapeutics Inc ์ •๋ณด๎˜

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
์ข…๋ชฉ ์ฝ”๋“œ RPTX
ํšŒ์‚ฌRepare Therapeutics Inc
CEOForte (Steve)
์›น์‚ฌ์ดํŠธhttps://www.reparerx.com/

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Repare Therapeutics Inc(RPTX)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Repare Therapeutics Inc(RPTX)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 2.65์ž…๋‹ˆ๋‹ค.

Repare Therapeutics Inc์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Repare Therapeutics Inc์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” RPTX์ž…๋‹ˆ๋‹ค.

Repare Therapeutics Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Repare Therapeutics Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 2.66์ž…๋‹ˆ๋‹ค.

Repare Therapeutics Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Repare Therapeutics Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 0.89์ž…๋‹ˆ๋‹ค.

Repare Therapeutics Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Repare Therapeutics Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ 114.24M์ž…๋‹ˆ๋‹ค.

Repare Therapeutics Inc(RPTX)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Repare Therapeutics Inc(RPTX)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ -2.00์ž…๋‹ˆ๋‹ค.